VINC vs. TRVN, PTPI, SYRS, SRNE, BIOR, HEPA, BPTSY, VRPX, VIRX, and TFFP
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Trevena (TRVN), Petros Pharmaceuticals (PTPI), Syros Pharmaceuticals (SYRS), Sorrento Therapeutics (SRNE), Biora Therapeutics (BIOR), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Virpax Pharmaceuticals (VRPX), Viracta Therapeutics (VIRX), and TFF Pharmaceuticals (TFFP). These companies are all part of the "pharmaceutical products" industry.
Vincerx Pharma vs. Its Competitors
Trevena (NASDAQ:TRVN) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.
In the previous week, Vincerx Pharma had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for Trevena. Trevena's average media sentiment score of 1.08 beat Vincerx Pharma's score of 0.64 indicating that Trevena is being referred to more favorably in the media.
13.6% of Trevena shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Trevena's return on equity of 0.00% beat Vincerx Pharma's return on equity.
Trevena presently has a consensus price target of $5.00, indicating a potential upside of 436.48%. Vincerx Pharma has a consensus price target of $40.00, indicating a potential upside of 92,923.26%. Given Vincerx Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Vincerx Pharma is more favorable than Trevena.
Vincerx Pharma has lower revenue, but higher earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.
Trevena has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.
Summary
Vincerx Pharma beats Trevena on 10 of the 14 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VINC) was last updated on 7/16/2025 by MarketBeat.com Staff
Free VINC Stock Alerts